|
122 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
12 Trials |
|
2436 News |
|
| «12345678910111213...4950» |
- atorvastatin / Generic mfg.
Trial primary completion date: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Jan 17, 2017
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
Trial primary completion date: Oct 2016 --> Oct 2017
- Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=25, Completed, Sponsor: University of California, Davis
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Dec 2010 --> Sep 2010
- lopinavir/ritonavir / Generic mfg.
Phase classification, Combination therapy: GW873140 In Combination With Kaletra In HIV Infected Subjects (clinicaltrials.gov) - Jan 17, 2017
P2b, N=175, Terminated, Sponsor: ViiV Healthcare
Trial primary completion date: Dec 2010 --> Sep 2010 Phase classification: P2 --> P2b
- lopinavir/ritonavir / Generic mfg.
Trial completion: Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon (clinicaltrials.gov) - Jan 12, 2017
P=N/A, N=141, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Phase classification: P2 --> P2b Active, not recruiting --> Completed
- Trial primary completion date: INTESTIPAX: IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=45, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Jul 2017
- | dronabinol oral / Generic mfg.
Trial completion: Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS (clinicaltrials.gov) - Jan 10, 2017
P1/2, N=30, Completed, Sponsor: National Institute on Drug Abuse (NIDA)
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Completed
- |||| Trial completion: Lactoferrin Treatment in HIV Patients (clinicaltrials.gov) - Dec 22, 2016
P2, N=56, Completed, Sponsor: Jason Baker
Recruiting --> Completed Recruiting --> Completed
- efavirenz / Generic mfg.
Phase classification, Enrollment change, IO biomarker: Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status (clinicaltrials.gov) - Dec 16, 2016
P1, N=34, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Phase classification: P1/2 --> P1 | N=44 --> 34
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) (clinicaltrials.gov) - Dec 15, 2016
P2, N=79, Completed, Sponsor: Westat
Phase classification: P1/2 --> P1 | N=44 --> 34 Active, not recruiting --> Completed
- Crixivan (indinavir sulfate) / Merck (MSD)
Trial withdrawal: A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113) (clinicaltrials.gov) - Dec 14, 2016
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Completed --> Withdrawn
- tenofovir disoproxil fumarate / Generic mfg.
Enrollment change, Trial withdrawal: Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia (clinicaltrials.gov) - Dec 14, 2016
P2/3, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed --> Withdrawn N=960 --> 0 | Terminated --> Withdrawn
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion, IO biomarker: Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV (clinicaltrials.gov) - Dec 13, 2016
P2, N=92, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=960 --> 0 | Terminated --> Withdrawn No longer recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: Accuracy of Portable Colposcopy and HPV Genotypes Among HIV+ Women (clinicaltrials.gov) - Dec 7, 2016
P=N/A, N=132, Terminated, Sponsor: Duke University
No longer recruiting --> Completed N=500 --> 132 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Feb 2016; Funding unavailable to perform study.
- |||| Prezista (darunavir) / J&J
Trial completion, Enrollment change: A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista (clinicaltrials.gov) - Dec 5, 2016
P4, N=225, Completed, Sponsor: Janssen Korea, Ltd., Korea
N=500 --> 132 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Feb 2016; Funding unavailable to perform study. Active, not recruiting --> Completed | N=3000 --> 225
- Trial completion, Trial primary completion date: IDEAL-Study: Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (clinicaltrials.gov) - Nov 28, 2016
P4, N=61, Completed, Sponsor: Universit
Active, not recruiting --> Completed | N=3000 --> 225 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> May 2015
- Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Enrollment change, Trial initiation date, Trial primary completion date: STERAL: Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection (clinicaltrials.gov) - Nov 22, 2016
P4, N=45, Active, not recruiting, Sponsor: Juan Mac
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> May 2015 Not yet recruiting --> Active, not recruiting | N=96 --> 45 | Initiation date: Nov 2013 --> Nov 2014 | Trial primary completion date: Jan 2015 --> Mar 2017
- | Vitekta (elvitegravir) / Japan Tobacco, Gilead
Enrollment change, Trial primary completion date: Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants (clinicaltrials.gov) - Nov 21, 2016
P2/3, N=31, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Active, not recruiting | N=96 --> 45 | Initiation date: Nov 2013 --> Nov 2014 | Trial primary completion date: Jan 2015 --> Mar 2017 N=90 --> 31 | Trial primary completion date: Jul 2016 --> Feb 2017
- Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Nov 9, 2016
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=90 --> 31 | Trial primary completion date: Jul 2016 --> Feb 2017 Trial primary completion date: Mar 2017 --> Sep 2017
- Trial primary completion date, Discordant: Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples (clinicaltrials.gov) - Nov 7, 2016
P1, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: May 2008 --> Jul 1999
- Trial completion: A Study of HIV in Newly Infected Individuals (clinicaltrials.gov) - Nov 7, 2016
P=N/A, N=0, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: May 2008 --> Jul 1999 Active, not recruiting --> Completed
- Trial primary completion date, HEOR: Medical Marijuana Use in HIV+ Patients Prospective Cohort Study (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Wayne State University
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Jun 2017
- Trial primary completion date: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=2016, Recruiting, Sponsor: University of Zurich
Trial primary completion date: Sep 2016 --> Jun 2017 Trial primary completion date: Dec 2015 --> Jan 2025
- Enrollment change, Trial termination, Trial primary completion date: A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts (clinicaltrials.gov) - Nov 2, 2016
P4, N=50, Terminated, Sponsor: University of British Columbia
Trial primary completion date: Dec 2015 --> Jan 2025 N=242 --> 50 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Jan 2012; There was no clear benefit but numerous side effects.
- Trial completion: Collection of Blood Samples From SMART Study Participants for Future Genetic Studies (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=3261, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=242 --> 50 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Jan 2012; There was no clear benefit but numerous side effects. Active, not recruiting --> Completed
- |||| Fuzeon (enfuvirtide) / Roche
Trial completion: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients (clinicaltrials.gov) - Nov 1, 2016
P2, N=64, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed No longer recruiting --> Completed
- Trial completion: A Test of Behavioral Intervention for Women at High Risk for HIV Infection (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=180, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Discordant: Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples (clinicaltrials.gov) - Oct 31, 2016
P1, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- zidovudine / Generic mfg.
Trial completion: A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=0, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- valacyclovir / Generic mfg.
Trial primary completion date: Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals? (clinicaltrials.gov) - Oct 31, 2016
P3, N=202, Active, not recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Mar 2017
- || emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial primary completion date: A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=400, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Sep 2016 --> Jun 2017
- ASC-09 / J&J
Trial withdrawal, Combination therapy: PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354. (clinicaltrials.gov) - Oct 28, 2016
P1, N=0, Withdrawn, Sponsor: Tibotec Pharmaceuticals, Ireland
Trial primary completion date: Sep 2016 --> Jun 2017 Terminated --> Withdrawn
- AGS-004 / CoImmune
Trial completion, Enrollment change, Trial primary completion date: A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004 (clinicaltrials.gov) - Oct 28, 2016
P1/2, N=6, Completed, Sponsor: Cynthia L Gay, MD
Terminated --> Withdrawn Recruiting --> Completed | N=12 --> 6 | Trial primary completion date: Dec 2016 --> May 2016
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion: A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=25, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Completed | N=12 --> 6 | Trial primary completion date: Dec 2016 --> May 2016 Recruiting --> Completed
- Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - Oct 27, 2016
P2b, N=71, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Recruiting --> Completed Trial primary completion date: Feb 2016 --> Jan 2017
- Trial completion: A Randomized Controlled Trial of the Bruthas Project (clinicaltrials.gov) - Oct 27, 2016
P2, N=396, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Feb 2016 --> Jan 2017 Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Enrollment open, Trial primary completion date, Metastases: A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter na (clinicaltrials.gov) - Oct 27, 2016
P3, N=350, Recruiting, Sponsor: University of Modena and Reggio Emilia
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2016
- Trial completion, Enrollment change: MACS: Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=407, Completed, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2016 Active, not recruiting --> Completed | N=600 --> 407
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment open, Trial initiation date: PrEP-India: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India (clinicaltrials.gov) - Oct 26, 2016
P0, N=2000, Recruiting, Sponsor: University of Manitoba
Active, not recruiting --> Completed | N=600 --> 407 Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jan 2016
- Trial completion: MICROBREAK1: Prevalence of Cerebral Small Vessel Disease in HIV Infected Patients (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=655, Completed, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jan 2016 Recruiting --> Completed
- Trial completion: DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=201, Completed, Sponsor: University of Delaware
Recruiting --> Completed Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date, HEOR, Adherence: HOST: Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=445, Completed, Sponsor: Triple O Research Institute PA
Recruiting --> Completed Recruiting --> Completed | N=650 --> 445 | Trial primary completion date: Apr 2015 --> Oct 2016
- ||| Prezista (darunavir) / J&J
Enrollment closed: A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista (clinicaltrials.gov) - Oct 17, 2016
P4, N=3000, Active, not recruiting, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Completed | N=650 --> 445 | Trial primary completion date: Apr 2015 --> Oct 2016 Recruiting --> Active, not recruiting
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: PREP-5: PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 (clinicaltrials.gov) - Oct 17, 2016
P4, N=52, Completed, Sponsor: St. Michael's Hospital, Toronto
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial primary completion date, Combination therapy: Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients (clinicaltrials.gov) - Oct 13, 2016
P1, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Oct 2015
- || emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed: A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication (clinicaltrials.gov) - Oct 13, 2016
P=N/A, N=400, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Apr 2015 --> Oct 2015 Recruiting --> Active, not recruiting
- Trial completion: Heterosexual HIV Transmission Study (HATS) (clinicaltrials.gov) - Oct 6, 2016
P=N/A, N=0, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change, Trial termination: Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy (clinicaltrials.gov) - Oct 4, 2016
P1, N=14, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed N=70 --> 14 | Recruiting --> Terminated
- Enrollment closed, Enrollment change: IDEAL-Study: Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (clinicaltrials.gov) - Sep 30, 2016
P4, N=61, Active, not recruiting, Sponsor: Universit
N=70 --> 14 | Recruiting --> Terminated Recruiting --> Active, not recruiting | N=210 --> 61
- Trial completion: Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow (clinicaltrials.gov) - Sep 30, 2016
P=N/A, N=224, Completed, Sponsor: University of Missouri-Columbia
Recruiting --> Active, not recruiting | N=210 --> 61 Withdrawn --> Completed
- Trial completion, Trial primary completion date: Asha HIV Health Promotion Intervention in India (clinicaltrials.gov) - Sep 28, 2016
P1/2, N=68, Completed, Sponsor: University of California, Los Angeles
Withdrawn --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2011 --> Mar 2011